ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,712.20
-1.12%
US Tech 100
19,375.20
0.00%
다우존스 지수
42,454.79
-0.31%
Bitcoin
87,360.20
0.54%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. aTyr Pharma Inc (ATYR)

  7. aTyr Pharma Inc (ATYR) 뉴스

ATYR

aTyr Pharma (ATYR)

aTyr Pharma Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ATYR
일자시간출처헤드라인심볼기업
2025/03/2621:00GlobeNewswire Inc.aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod FranchiseNASDAQ:ATYRaTyr Pharma Inc
2025/03/2005:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ATYRaTyr Pharma Inc
2025/03/2005:11Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ATYRaTyr Pharma Inc
2025/03/2005:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATYRaTyr Pharma Inc
2025/03/1808:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2025/03/1406:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ATYRaTyr Pharma Inc
2025/03/1405:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
2025/03/1405:01GlobeNewswire Inc.aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate UpdateNASDAQ:ATYRaTyr Pharma Inc
2025/03/1305:00GlobeNewswire Inc.aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational MedicineNASDAQ:ATYRaTyr Pharma Inc
2025/03/0706:02GlobeNewswire Inc.aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:ATYRaTyr Pharma Inc
2025/03/0422:00GlobeNewswire Inc.aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial ResultsNASDAQ:ATYRaTyr Pharma Inc
2025/02/2422:00GlobeNewswire Inc.aTyr Pharma to Present at the Leerink Partners Global Healthcare ConferenceNASDAQ:ATYRaTyr Pharma Inc
2025/02/0508:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2025/02/0508:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2025/01/2922:00GlobeNewswire Inc.aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International ConferenceNASDAQ:ATYRaTyr Pharma Inc
2025/01/1106:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2025/01/1106:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2024/12/2406:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATYRaTyr Pharma Inc
2024/12/2406:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
2024/12/1722:00GlobeNewswire Inc.aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ATYRaTyr Pharma Inc
2024/12/1306:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2024/12/1306:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATYRaTyr Pharma Inc
2024/12/1306:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
2024/12/1306:00GlobeNewswire Inc.aTyr Pharma Announces the Appointment of Eric Benevich to its Board of DirectorsNASDAQ:ATYRaTyr Pharma Inc
2024/12/1022:00GlobeNewswire Inc.aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary SarcoidosisNASDAQ:ATYRaTyr Pharma Inc
2024/12/0922:00GlobeNewswire Inc.aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on FibrosisNASDAQ:ATYRaTyr Pharma Inc
2024/11/1522:00GlobeNewswire Inc.aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on FibrosisNASDAQ:ATYRaTyr Pharma Inc
2024/11/1508:51Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ATYRaTyr Pharma Inc
2024/11/0806:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATYRaTyr Pharma Inc
2024/11/0806:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATYRaTyr Pharma Inc
 검색 관련기사 보기:NASDAQ:ATYR

최근 히스토리

LSE
SPQH
Gx Spx Thedge
BIT
F16069
Vontobel Financial Produ...
USOTC
DNAG
DNAPrint Genomics (CE)
LSE
3DUS
Robeco 3dus
TG
398
Cricut
BIT
SG
SAES Getters
BIT
UB25VP
UniCredit Bank
BIT
F25579
Vontobel Financial Produ...
BIT
F39174
Vontobel Financial Produ...
BIT
SCOI5L
Societe Generale Effekten
BIT
UV8CQ0
UniCredit Bank
BIT
F34824
Vontobel Financial Produ...
BIT
S24890
SG ISSUER
BIT
P1OP72
BNP Paribas Issuance
BIT
S28266
Societe Generale Effekten
BIT
A29552
Aldburg Public
Delayed Upgrade Clock
ADVFN Logo
대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지